Moderna, Inc. vs Warner Music Group Corp — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: Moderna, Inc. is far larger — about 5.2× Warner Music Group Corp's market cap, and Warner Music Group Corp pays a 2.77% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Warner Music Group Corp for 96 Days on average.
| MRNA | WMG | |
|---|---|---|
Market Cap | $78.65B | $15.12B |
Volume | 37,373,437 | 2,966,414 |
Sector | Health | Media |
52-Week High | $203.46 | $34.72 |
52-Week Low | $22.36 | $23.65 |
Typical Hold Time | 59 Days | 96 Days |
Enterprise Value | $74.80B | $19.42B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Warner Music Group (WMG) trades at $28.91, up 2.66% on the day, with a bullish technical outlook and strong analyst support. Recent earnings have beaten expectations, with Q2 2026 EPS of $0.38 exceeding the $0.3435 forecast. The company's revenue growth is solid, projected to reach $7.3B in 2026, and it maintains a high return on equity of 92.72%. Positive news includes strategic AI partnerships and a renewed licensing deal with NetEase Cloud Music.
The stock presents a compelling opportunity with a consensus price target of $39.50, implying significant upside. However, risks include recent net cash outflows, a high P/E ratio of 23.12, and competitive pressures in the evolving music industry. Investor sentiment is buoyed by institutional buying and AI-driven growth prospects, but execution on cost management and streaming market share remains critical.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →